Advancing Next-Generation Bispecific Antibodies: From Rigidity to Flexibility for Differentiation & Clinical Translation

• Designing the strategy and target rationale of FlexiBody®, a multi-specific antibody platform
• Engineering considerations to optimize efficacy while mitigating on-target toxicity
• Exploring translational insights supporting clinical development and differentiation

Speakers:

Mingjiu Chen

Founder, Chairman & Chief Executive Officer

Biosion